Bispecific antibodies against cd20 and cd3 and their uses

Abstract

A bispecific antibody that specifically binds the surface antigen CD3 of immune cells and the CD20 antigen on the surface of tumor cells, and can bind to human CD3 with high affinity, induce T cell proliferation, and mediate tumor cell killing. The bispecific antibody can be used to mediate the specific killing of target cells by T cells in vitro, and the construction method is simple, which avoids the possibility of mismatch between the two groups of light chains and heavy chains of the heterobispecific antibody, thereby reducing the purification of the antibody. The obtained antibody has high affinity, little cytokine side effect and high safety.

Description

[0001] Related applications [0002] This application claims the priority of Chinese patent application CN 201811294887.4 filed on November 1, 2018. The contents of the above-referenced priority applications are incorporated herein by reference in their entirety. technical field [0003] The present invention relates to the field of immunology, more particularly, to a bispecific antibody against CD20 and CD3, and the use of said antibody, especially its use in the treatment of tumors. Background technique [0004] In the process of cellular immunity, T lymphocytes play an important role. The cellular immunity mediated by T cells is mainly through the specific recognition of antigen peptides presented by the major histocompatibility complex (MHC) on the cell surface through the T cell receptor (T cell receptor, TCR), thereby activating the intracellular T cell signal to specifically kill the target cells. This plays a vital role in removing diseased cells in the body in t...

AI Technical Summary

Problems solved by technology

Although anti-CD20 tumor targeting strategies have shown great potential in clinical application, not all patients respond to anti-CD20 therapy, and some patients show resistance to anti-CD20 therapy (eg, to rituximab resistant)

Images